Alterity Therapeutics launches phase 2 trial of MSA candidate ATH434
Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in patients with multiple system atrophy (MSA). According ... Read More
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple ... Read More
Prana Biotechnology secures FDA orphan drug status for PBT434 to treat multiple system atrophy
In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at ... Read More